Westpac Banking Corp (ASX: WBC) shares have had a solid run, and for many investors it has done exactly what a big bank is supposed to do. It has paid dividends, offered stability, and benefited from a strong banking cycle. But looking ahead, I'm not convinced the risk-reward is especially compelling from here.
If I were choosing where to put new money today, I'd rather focus on blue-chip ASX shares with clearer growth runways and less reliance on the domestic credit cycle. These are three established, high-quality ASX names I'd choose instead.
Image source: Getty Images
ResMed Inc. (ASX: RMD)
ResMed is one of those rare ASX shares that is genuinely global, and that matters. The business operates in a large and growing market driven by ageing populations, rising obesity rates, and increasing awareness of sleep apnoea.
What really appeals to me is that ResMed's growth is not dependent on economic conditions in Australia. Demand for sleep and respiratory devices is structural, not cyclical. Its recent results showed solid device growth, expanding digital health adoption, and improving margins.
Unlike a bank, ResMed is not constrained by regulatory capital rules or housing credit growth. It has the ability to reinvest heavily in innovation while still generating strong cash flow. For long-term investors, that combination is powerful.
Goodman Group (ASX: GMG)
Goodman is another blue-chip ASX share I'd rather own than Westpac shares.
Its focus on high-quality industrial property, logistics assets, and data centre infrastructure places it right in the middle of some of the most attractive long-term trends in global real estate. Ecommerce, supply chain reconfiguration, and cloud computing all require exactly the types of assets Goodman specialises in.
What sets Goodman apart is its development capability and global footprint. It is not just a passive landlord. It actively creates assets for customers, often alongside capital partners, which drives higher returns on equity over time.
In contrast to Westpac, Goodman's growth is not tied to interest margins or mortgage volumes. It's tied to long-term demand for infrastructure that underpins the modern economy.
Sigma Healthcare Ltd (ASX: SIG)
Sigma has quietly transformed itself over the past year, and I think the market is still adjusting to what the business has become.
The merger with Chemist Warehouse has created a vertically integrated healthcare group with scale across wholesale distribution, franchising, and retail. Pharmacy demand is resilient, supported by demographics and recurring consumer needs rather than economic cycles.
What I like about Sigma today is that it combines defensive characteristics with genuine operational upside. As integration benefits flow through and efficiencies are realised, earnings growth does not need bold assumptions to improve.
Compared to a major bank, Sigma offers exposure to healthcare demand rather than housing credit, and that diversification matters in a long-term portfolio.
Foolish takeaway
Westpac is not a bad business. But at this point in the cycle, I'd rather back blue-chip ASX shares with clearer growth drivers and less dependence on the domestic banking environment.
ResMed offers global healthcare growth, Goodman provides exposure to critical infrastructure, and Sigma brings defensive demand with improving fundamentals. For me, that's a more attractive mix than simply adding more exposure to a major bank.
